The promise of selective aldosterone synthase inhibition for the management of resistant hypertension
- PMID: 36540035
- DOI: 10.1093/eurheartj/ehac754
The promise of selective aldosterone synthase inhibition for the management of resistant hypertension
Conflict of interest statement
Conflict of Interest: All authors declare no conflict of interest for this contribution.
Comment on
-
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7. N Engl J Med. 2023. PMID: 36342143 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical